MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
August 07 2020 - 5:00PM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with diabetes and orphan lung
diseases, announced today that its Chief Executive Officer, Michael
Castagna, PharmD, will participate in a Fireside Chat at the BTIG
Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020
at 2:00 pm (ET). Interested parties can access a link to the live
webcast of the presentation from the Events & Presentations
section of the Company's website at http://www.mannkindcorp.com.
The webcast replay will remain available for 14 days following the
live presentation.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. MannKind is headquartered in Westlake
Village, California, and has a state-of-the art manufacturing
facility in Danbury, Connecticut. The Company also employs field
sales and medical representatives across the U.S. For further
information, visit www.mannkindcorp.com.
Company
Contact:818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024